Abstract
Objective
The aim of this study was to establish the degree of hypothalamic-pituitary-adrenal (HPA) axis suppression occurring with low oral doses of betamethasone over 5 days. Prednisolone 10mg was used as a comparator as it is considered a well tolerated short-course therapy for atopic conditions.
Study Design and Participants
50 healthy adult volunteers not on cortico-steroid therapy were randomised to five treatment groups of 10 volunteers each to receive either oral betamethasone 0.25mg, 0.5mg, l.0mg or 2.0mg, or oral prednisolone 10mg.
Interventions and Measurements
Serum cortisol was measured in samples collected between 7am and 8am on days 1, 2, 3, 5 and 8. Tetracosactide (Synachten®, Novartis) was used in physiological concentrations (i.e. 1 mg/L intravenously) to elicit adrenal cortisol release at baseline and again on day 8 to test for drug-induced suppression. Blood samples were collected at 30 and 60 minutes to evaluate the serum cortisol response. Overnight urine was collected for the calculation of the urine cortisol: creatinine ratio on days 1, 5, 8,10,15 and 21.
Results
On both day 1 (baseline) and day 8 tetracosactide elicited similar increases in serum cortisol levels at 30 minutes in all five treatment groups, suggesting a normal physiological response. However, the 30-minute post-stimulation serum cortisol levels in the groups receiving betamethasone 1mg and 2mg did not reach the cited normal values, i.e. above 500 nmol/L, on day 8. Urine cortisol: creatinine ratios were significantly suppressed by betamethasone land 2mg on days 5 and 8, respectively. Serum cortisol levels were significantly reduced in all treatment groups, but returned to normal by day 8 in all groups except in the betamethasone 2mg group. The urine cortisol: creatinine ratios returned to normal by day 15 in the betamethasone 2mg group.
Conclusions
The extent of suppression of serum cortisol was similar with betamethasone 0.25mg, 0.5mg and lmg and prednisolone 10mg. Betamethasone 2mg had more pronounced effects on serum cortisol levels and urine cortisol: creatinine ratios. These findings, therefore, indicate mild adrenal suppression after a 5-day oral course of therapy, but with rapid recovery thereafter. This indicates a normal adrenal reserve and thus short courses of low-dose betamethasone may be considered a well tolerated treatment for atopic diseases in otherwise healthy individuals.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ohlander BO, Hansson RE, Karlsson KE. A comparison of three injectable corticosteroids for the treatment of patients with seasonal hay fever. J Int Med Res 1980; 8: 63–9
Mygind N, Dahl R, Nielsen LP, et al.. Effect of corticosteroids on nasal blockage in rhinitis measured by objective methods. Allergy 1997; 52(S40): 30–44
Mygind N, Laursen LC, Dahl M. Systemic corticosteroid treatment for seasonal allergic rhinitis: a common but poorly documented therapy. Allergy 2000; 55: 11–15
Mygind N, Dahl R, Pedersen S, et al., editors. Rhinitis, in Essential Allergy. Oxford: Blackwell Science Ltd1995: 229–30
Downie WW, Dixon JG, Lowe JR, et al. Adrenocortical suppression by synthetic corticosteroid drugs: a comparative study of prednisolone and betamethasone. Br J Clin Pharmacol 1978; 6: 397–9
Schimmer BP, Parker KL. Adrenocorticotropic hormes; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill 1995: 1459–85
Honour JW. Hypothalamic-pituitary-adrenal axis. Resp Med 1994; 88: 9–15
Streeten DHP. What test for hypothalamic-pituitary-adreno-cortical insufficiency? Lancet 1999; 354: 179–80
Broide J, Soferman R, Kivity S, et al. Low-dose adreno-corticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metabolism 1995; 80(4): 1243–6
McIntyre DH, Mitchell CA, Bowler SD, et al. Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens. Thorax 1997; 52: 550–8
Daniel WW. Applied nonparametric statistics. 2nd ed. Boston: PWS Kent 1990: 45–9
Oelkers W. Adrenal insufficiency. N Eng J Med 1996; 1206–12
Clark DJ, Lipworth BJ. Evaluation of corticotrophin releasing factor stimulation and basal markers of hypothalamic— pituitary—adrenal axis suppression in asthmatic patients. Chest 1997; 112: 1248–52
Grove A, Allam C, McFarlane LC, et al. A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br J Clin Pharmacol 1994; 38: 527–32
Jennings BH, Anderson KE, Johansson SA. Assessment of the systemic effects of inhaled glucocorticosteroids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol 1991; 40: 77–82
Acknowledgements
The Authors thank Mrs J. Bekker for secretarial support and Schering-Plough (Pty) Ltd for financial support and supply of test drugs. The study selection, analysis, interpretation of results and manuscript preparation were entirely under the control of the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Snyman, J.R., De Sommers, K., van Wyk, M. et al. Short-Course, Low-Dose Betamethasone Therapy Causes only Marginal and Transient Hypothalamic-Pituitary-Adrenal-Axis Suppression. Clin. Drug Investig. 21, 499–504 (2001). https://doi.org/10.2165/00044011-200121070-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200121070-00005